

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
09 March 2023 (09.03.2023)



(10) International Publication Number
WO 2023/034992 A1

(51) International Patent Classification:

C07D 403/12 (2006.01) C07D 417/12 (2006.01)
C07D 405/14 (2006.01) C07D 417/14 (2006.01)
C07D 409/14 (2006.01) C07F 9/00 (2006.01)
C07D 413/12 (2006.01) A61K 31/4155 (2006.01)

(21) International Application Number:

PCT/US2022/075945

(22) International Filing Date:

02 September 2022 (02.09.2022)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/240,765 03 September 2021 (03.09.2021) US

(71) Applicant: **GENZYME CORPORATION** [US/US]; 450 Water Street, Cambridge, Massachusetts 02141 (US).

(72) Inventors: **LIAO, Junkai**; c/o Genzyme Corporation, 450 Water Street, Cambridge, Massachusetts 02141 (US). **MUNSON, Mark**; c/o Genzyme Corporation, 450 Water Street, Cambridge, Massachusetts 02141 (US). **THURAIRATNAM, Sukanthini**; c/o Genzyme Corporation, 450 Water Street, Cambridge, Massachusetts 02141 (US). **HIRTH, Bradford**; c/o Genzyme Corporation, 450 Water Street, Cambridge, Massachusetts 02141 (US). **GAO, Zhongli**; c/o Genzyme Corporation, 450 Water Street, Cambridge, Massachusetts 02141 (US). **HURLBUT, Gregory**; c/o Genzyme Corporation, 450 Water Street, Cambridge, Massachusetts 02141 (US). **BORCHERDING, David**; c/o Genzyme Corporation, 450 Water Street, Cambridge, Massachusetts 02141 (US). **BARRAGUE, Matthieu**; c/o Genzyme Corporation, 450 Water Street, Cambridge, Massachusetts 02141 (US). **GILLESPIE, Timothy Alan**; c/o Genzyme Corporation, 450 Water Street, Cambridge, Massachusetts 02141 (US). **GROSS, Alexandre**; c/o Genzyme Corporation, 450 Water Street, Cambridge, Massachusetts 02141 (US). **GOOD, Andrew**; c/o Genzyme Corporation, 450 Water Street, Cambridge, Massachusetts 02141 (US). **VAZ, Roy**; c/o Genzyme Corporation, 450 Water Street, Cambridge, Massachusetts 02141 (US). **LIU, Jinyu**; c/o Genzyme Corporation, 450 Water Street, Cambridge, Massachusetts 02141 (US). **LI, Yi**; c/o Genzyme Corporation, 450 Water Street, Cambridge, Massachusetts 02141 (US). **METZ, Markus**; c/o Genzyme Corporation, 450 Water Street, Cambridge, Massachusetts 02141 (US). **RUVINSKY, Anatoly**; c/o Genzyme Corporation, 450 Water Street, Cambridge, Massachusetts 02141 (US). **BARBERIS, Claude**; c/o Genzyme Corporation, 450 Water Street, Cambridge, Massachusetts 02141 (US).

(74) Agent: **HALEY, Christopher Keating** et al.; Goodwin Procter LLP, 100 Northern Avenue/IP Docketing 7th fl, Boston, Massachusetts 02210 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: INDOLE COMPOUNDS AND METHODS OF USE

(57) Abstract: The invention relates to heterocyclic compounds, pharmaceutically acceptable salts thereof, and pharmaceutical preparations thereof. Also described herein are compositions and the use of such compounds in methods of treating diseases and conditions mediated by deficient CFTR activity, in particular cystic fibrosis.



WO 2023/034992 A1